FDA outlines plan to phase out animal testing in new draft guidance
The US Food and Drug Administration (FDA) has advanced its plan to phase out animal testing by debuting draft guidance…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
CellProthera sets the scene for Phase III stem cell therapy trial
CellProthera is set to begin a Phase III study exploring the potential of its stem cell therapy in patients with…
-
Structure’s obesity pill prompts 16.3% weight loss in Phase II
Structure Therapeutics’ oral weight loss drug, aleniglipron, has prompted strong weight loss in a Phase II obesity trial – a…
-
Bayer eyes label expansion on Phase III non-diabetic CKD win
Bayer is looking to expand the use case of its non-steroidal chronic kidney disease (CKD) drug, Kerendia (finerenone), to non-diabetic…
-
Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination
Australian biotech Immutep has terminated a late-stage study evaluating its lead oncology candidate, eftilagimod alfa (efti), in combination with MSD’s…
-
Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial…
-
UCB’s Bimzelx bests Skyrizi in Phase III PsA study, but analysts sceptical
UCB’s top-selling drug Bimzelx (bimekizumab) has bested AbbVie’s blockbuster immunology drug, Skyrizi (risankizumab), during a head-to-head study in psoriatic arthritis…
-
UK health authorities join forces to champion foreign infectious disease trials
Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa,…
-
Pfizer’s trispecific heads to Phase III on mid-stage AD success
American pharmaceutical giant Pfizer is planning to take its trispecific antibody, tilrekimig, to Phase III in atopic dermatitis (AD) as…
-
Analysts tout market potential of Xenon’s epilepsy drug on Phase III win
Analysts have touted the market potential of Xenon Pharmaceuticals’ novel epilepsy drug, azetukalner, following a positive late-stage readout in patients…